Basic information Source Reactivity Background References Safety Supplier Related

VEGFB Antibody

Basic information Source Reactivity Background References Safety Supplier Related

VEGFB Antibody Basic information

Product Name:
VEGFB Antibody
Synonyms:
  • VEGFB Antibody
MW:
0
Mol File:
Mol File
More
Less

VEGFB Antibody Usage And Synthesis

Source

Rabbit

Reactivity

Human

Background

Vascular endothelial growth factor is a highly specific mitogen for vascular endothelial cells. VEGF and its close relatives VEGF-B, -C and -D form a subfamily within PDGF family of growth factors, which belongs to the cysteine knot class of cytokines. Five VEGF isoforms of 121, 145, 165, 189 and 206 amino acids are generated as a result of alternative splicing from a single VEGF gene.The various VEGF forms bind to three tyrosine-kinase receptors, VEGFR-1, VEGFR-2 and VEGFR-3 which are expressed almost exclusively in endothelial cells. VEGFR-2 is the main angiogenic signal transducer for VEGF, while VEGFR-3 is specific for VEGF-C and -D and is necessary and sufficient for lymphangiogenic signaling. However, upon proteolytic processing VEGF-C and -D gain the ability to also bind and activate VEGFR-2. Guided by the binding properties of the ligands, the VEGFRs are able to form both homodimers and heterodimers. Receptor dimerization is accompanied by activation of receptor kinase activity leading to receptor autophosphorylation. Phosphorylated receptors recruit interacting proteins and induce downstream signaling. Recently, tumor therapies based on neutralizing anti-VEGF antibodies and small molecule tyrosine kinase inhibitors targeting VEGFRs have been developed. These new strategies for tumor treatment show the clinical relevance of inhibiting VEGF signal transduction pathways that are exaggerated in pathological angiogenesis.

References

[1] Olsson, A.K. et al. (2006) Nat. Rev. Mol. Cell Biol. 7, 359-371.
[2] Gluzman-Poltorak, Z. et al. (2001) J. Biol. Chem. 276, 18688-18694.
[3] Matsumoto, T. and Mugishima, H. (2006) J. Atheroscler. Thromb. 13, 130-135.
[4] Gatto, B. and Cavalli, M. (2006) Anticancer Agents Med. Chem. 6, 287-301.

VEGFB AntibodySupplier

Absin Bioscience Inc.
Tel
021-38015121 18438616290
Email
lanwu@univ-bio.com
Shanghai Universal Biotech Co.,Ltd
Tel
15921930842 15921930842
Email
yh-wang@univ-bio.com
Hubei ipodix Biotech Technology Co., Ltd
Tel
18007124176
Email
ipdshengwu@163.com
CUSABIO TECHNOLOGY LLC
Tel
027-87196173
Email
cusabio@163.com
Hubei Serenity BioSolutions Co., Ltd.
Tel
027-19371278702 18008634902
Email
19384116026@163.com